Cargando…

The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up

The use of vaccines has allowed the containment of coronavirus disease 2019 (COVID-19) at a global level. The present work aims to add data on vaccination by evaluating the level of neutralizing antibodies in individuals who have received a three-vaccination series. For this purpose, we ran a survei...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolai, Eleonora, Tomassetti, Flaminia, Pelagalli, Martina, Sarubbi, Serena, Minieri, Marilena, Nisini, Alberto, Nuccetelli, Marzia, Ciotti, Marco, Pieri, Massimo, Bernardini, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604657/
https://www.ncbi.nlm.nih.gov/pubmed/37893035
http://dx.doi.org/10.3390/biomedicines11102661
_version_ 1785126887300792320
author Nicolai, Eleonora
Tomassetti, Flaminia
Pelagalli, Martina
Sarubbi, Serena
Minieri, Marilena
Nisini, Alberto
Nuccetelli, Marzia
Ciotti, Marco
Pieri, Massimo
Bernardini, Sergio
author_facet Nicolai, Eleonora
Tomassetti, Flaminia
Pelagalli, Martina
Sarubbi, Serena
Minieri, Marilena
Nisini, Alberto
Nuccetelli, Marzia
Ciotti, Marco
Pieri, Massimo
Bernardini, Sergio
author_sort Nicolai, Eleonora
collection PubMed
description The use of vaccines has allowed the containment of coronavirus disease 2019 (COVID-19) at a global level. The present work aims to add data on vaccination by evaluating the level of neutralizing antibodies in individuals who have received a three-vaccination series. For this purpose, we ran a surveillance program directed at measuring the level of IgG Abs against the Receptor Binding Domain (RBD) and surrogate virus neutralizing Ab (sVNT) anti-SARS-CoV-2 in the serum of individuals undergoing vaccination. This study was performed on employees from the University of Rome Tor Vergata and healthcare workers from the University Hospital who received the Vaxzevria vaccine (n = 56) and Comirnaty vaccine (n = 113), respectively. After the second dose, an increase in both RBD and sVNT Ab values was registered. In individuals who received the Comirnaty vaccine, the antibody titer was about one order of magnitude higher after 6 months from the first dose. All participants in this study received the Comirnaty vaccine as the third dose, which boosted the antibody response. Five months after the third dose, nearly one year from the first injection, the antibody level was >1000 BAU/mL (binding antibody units/mL). According to the values reported in the literature conferring protection against SARS-CoV-2 infection, our data indicate that individuals undergoing three vaccine doses present a low risk of infection.
format Online
Article
Text
id pubmed-10604657
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106046572023-10-28 The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up Nicolai, Eleonora Tomassetti, Flaminia Pelagalli, Martina Sarubbi, Serena Minieri, Marilena Nisini, Alberto Nuccetelli, Marzia Ciotti, Marco Pieri, Massimo Bernardini, Sergio Biomedicines Article The use of vaccines has allowed the containment of coronavirus disease 2019 (COVID-19) at a global level. The present work aims to add data on vaccination by evaluating the level of neutralizing antibodies in individuals who have received a three-vaccination series. For this purpose, we ran a surveillance program directed at measuring the level of IgG Abs against the Receptor Binding Domain (RBD) and surrogate virus neutralizing Ab (sVNT) anti-SARS-CoV-2 in the serum of individuals undergoing vaccination. This study was performed on employees from the University of Rome Tor Vergata and healthcare workers from the University Hospital who received the Vaxzevria vaccine (n = 56) and Comirnaty vaccine (n = 113), respectively. After the second dose, an increase in both RBD and sVNT Ab values was registered. In individuals who received the Comirnaty vaccine, the antibody titer was about one order of magnitude higher after 6 months from the first dose. All participants in this study received the Comirnaty vaccine as the third dose, which boosted the antibody response. Five months after the third dose, nearly one year from the first injection, the antibody level was >1000 BAU/mL (binding antibody units/mL). According to the values reported in the literature conferring protection against SARS-CoV-2 infection, our data indicate that individuals undergoing three vaccine doses present a low risk of infection. MDPI 2023-09-28 /pmc/articles/PMC10604657/ /pubmed/37893035 http://dx.doi.org/10.3390/biomedicines11102661 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nicolai, Eleonora
Tomassetti, Flaminia
Pelagalli, Martina
Sarubbi, Serena
Minieri, Marilena
Nisini, Alberto
Nuccetelli, Marzia
Ciotti, Marco
Pieri, Massimo
Bernardini, Sergio
The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up
title The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up
title_full The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up
title_fullStr The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up
title_full_unstemmed The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up
title_short The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up
title_sort antibodies’ response to sars-cov-2 vaccination: 1-year follow up
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604657/
https://www.ncbi.nlm.nih.gov/pubmed/37893035
http://dx.doi.org/10.3390/biomedicines11102661
work_keys_str_mv AT nicolaieleonora theantibodiesresponsetosarscov2vaccination1yearfollowup
AT tomassettiflaminia theantibodiesresponsetosarscov2vaccination1yearfollowup
AT pelagallimartina theantibodiesresponsetosarscov2vaccination1yearfollowup
AT sarubbiserena theantibodiesresponsetosarscov2vaccination1yearfollowup
AT minierimarilena theantibodiesresponsetosarscov2vaccination1yearfollowup
AT nisinialberto theantibodiesresponsetosarscov2vaccination1yearfollowup
AT nuccetellimarzia theantibodiesresponsetosarscov2vaccination1yearfollowup
AT ciottimarco theantibodiesresponsetosarscov2vaccination1yearfollowup
AT pierimassimo theantibodiesresponsetosarscov2vaccination1yearfollowup
AT bernardinisergio theantibodiesresponsetosarscov2vaccination1yearfollowup
AT nicolaieleonora antibodiesresponsetosarscov2vaccination1yearfollowup
AT tomassettiflaminia antibodiesresponsetosarscov2vaccination1yearfollowup
AT pelagallimartina antibodiesresponsetosarscov2vaccination1yearfollowup
AT sarubbiserena antibodiesresponsetosarscov2vaccination1yearfollowup
AT minierimarilena antibodiesresponsetosarscov2vaccination1yearfollowup
AT nisinialberto antibodiesresponsetosarscov2vaccination1yearfollowup
AT nuccetellimarzia antibodiesresponsetosarscov2vaccination1yearfollowup
AT ciottimarco antibodiesresponsetosarscov2vaccination1yearfollowup
AT pierimassimo antibodiesresponsetosarscov2vaccination1yearfollowup
AT bernardinisergio antibodiesresponsetosarscov2vaccination1yearfollowup